HPD (HPB and Liver Transplant Surgery Padova)

Our fellow @a_mae0124 🇯🇵 🇮🇹 hitting the stage with her systematic review and meta analysis on treatment strategies for recurrent PDAC Great day at @JSHBPS2026 @JSHBPS in Nara 🦌

🔴 Post-Pancreatectomy liver injury (PPLI) might be a new significant entity in the modern era of pancreas cancer surgery with vascular resection 👉 Incidence 13% leading to ⬆️ mortality 🔜 More to come! sciencedirect.com/science/articl…

🎙️ @Gio_Marchegiani is an invited speaker at @JSHBPS in Nara 🇯🇵 to present a new concept of IPMN 🍇 recurrence after surgery Great time at @JSHBPS2026 thank you 😊 to the organizers for such an amazing opportunity

Alessandro Furlanetto on the stage of @JSHBPS 2026 in Nara 🇯🇵 His talk is about SMA approach of 🤖 Pancreatoduodenectomy @JSHBPS2026

And now @Giampaolo_Perri on our new protocol on risk based drain management 💦 to prevent and manage pancreatic fistula Great 😊 time at @JSHBPS @JSHBPS2026

Very busy and productive days at @JSHBPS 2026 in Nara 🦌 🇯🇵 Dr. Bassi presenting our experience in robotic total pancreatectomy and islet autotransplantation @JSHBPS2026

New evidence & perspectives on the definition and management of IPMN progression during follow-up ✍️ 🔍 What is the optimal surveillance strategy?
🔪 When and how should we intervene surgically?
🤔 What should actually be defined as so-called “recurrence”? Still many unanswered questions and much to discuss 💪🏼 #JSHBPS2026 @JSHBPS @JSHBPS2026 @Gio_Marchegiani

A new player has entered pancreatic surgery: Postpancreatectomy liver injury ☠️ ~ 50% related mortality Early detection with 🧪 and doppler 🔊 ⚖️ Next step? Standardized definition @ISGPS_news sciencedirect.com/science/articl…

Fantastic time in Geneva Switzerland 🇨🇭 for @_ILTS_ 2026 Truly unforgettable event with top notch experts in the field! @prof_cillo

Our Dr. Domenico Bassi visiting @go3245 in Tokyo 🇯🇵 for an intense week Dr. Alessandro Furlanetto is spending a 6-month fellowship focused on robotic HPB surgery 🎓🎓🎓

Quality metrics for perioperative red blood cell transfusion in gastrointestinal cancer surgery: international Delphi consensus ➡️doi.org/10.1093/bjsope… A consensus on quality metrics to assess and monitor the use of perioperative red blood cell transfusion (RBCT) in gastrointestinal cancer surgery was generated through a four-round modified Delphi process with 37 international experts. Consensus was reached on 18 quality metrics across structures, processes, and outcomes of care, reflecting both clinical importance and feasibility. These expert-endorsed metrics can support institutions and health systems in monitoring RBCT practices, with a view to reducing unwarranted variation in RBCT use and improving patient outcomes and blood resource stewardship in gastrointestinal cancer surgery. 👏👏👏@HalletJulie, @jesse_zuckerman , Frances C Wright , Jeannie Callum , Alyson L Mahar , Alexis F Turgeon , Asim Alam , Jessica Armah , @Gio_Marchegiani , David Cavallucci , Guillaume Martel on behalf of , the RBCT Quality Metrics Group #SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery

Great time at the @PancreasClub ✨✨✨

We will be there with our @prof_cillo See you in Geneva 🇨🇭

Join us at the #TransMedics Evening Symposium at the #ILTSCongress2026. OCS Liver Experience with 11,000 Liver Transplants – A New Standard of Care for Liver Transplantation Globally Date: May 7th | 18:15-19:30 | Room K More details at: #transmedics" target="_blank" rel="nofollow noopener">mcicanada.swoogo.com/2026-geneva/in…

Thank you @BjsOpen for featuring our paper!!!

WHEN THE BEST TREATMENT IS NO DELIVERABLE: RETHINKING DECISION-MAKING IN HCC I am pleased to share our recent publication in Hepatoma Research: In hepatocellular carcinoma (HCC), multidisciplinary tumour boards are now recognised as the cornerstone of treatment decision-making. Yet in real-world practice, some of the most influential determinants of therapeutic choice remain implicit and insufficiently structured. This work focuses on the concept of “treatment unfeasibility” as a central yet often overlooked dimension of clinical reasoning. Rather than a simple contraindication, unfeasibility emerges as a multidimensional construct shaped by four key domains: technical limitations, available resources, patient values and preferences, and broader societal factors, including equity and access to care. A critical insight is the frequent inverse relationship between therapeutic efficacy and feasibility, which contributes to the persistent undertreatment of HCC patients. Liver transplantation exemplifies this tension: it offers the highest curative potential yet remains inaccessible to many because of organ shortages, unequal resource distribution, and systemic disparities. By making these determinants explicit and structuring them within a coherent framework, this paper aims to move beyond purely algorithmic decision-making and to provide practical tools for integrating these factors into multidisciplinary discussions. Ultimately, improving HCC care requires not only identifying the best theoretical treatment but also ensuring that it is realistically deliverable for each individual patient. oaepublish.com/articles/2394-…

Our delegation in Skopje for the @EDSurgery @my_ueg postgraduate course 💪💪💪

🔵Vein resections ✂️are standard of care in pancreatectomy: what about TRUE infiltration role? 🔍 300 upfront resected veins 🇮🇹🇨🇳 🔬 66% path proven infiltration 🚨 True infiltration impairs survival 💉 adjuvant chemo prolongs it to 30 months link.springer.com/article/10.100…

🚨 Our new paper is out on @BjsOpen Postpancreatectomy diarrhoea: prospective, single-centre longitudinal analysis of incidence, risk factors, management, and impact on quality of life 🆓 full text available!!! academic.oup.com/bjsopen/articl…

New letter in Journal of Hepatology (w/ AR & PM) We respond to Mauro et al.’s framework for non-proportional hazards in pivotal HCC trials — and raise 8 methodological concerns: → p-values conflated with clinical relevance → GT test misused as a binary trigger → Internal numerical inconsistencies (CIs excluding null, yet p>0.05) → Retrospective questioning of pre-specified stopping rules → Selective inference in secondary analyses Bottom line: in NPH trials, data maturity, absolute effect size, and clinical applicability must all be evaluated — not just statistical significance. IMbrave050 says it all: MaxCombo p=0.018 at interim → p=0.326 at final analysis. GRADE tools already exist to flag this. Let’s use them. 🔬 @LorenzaRimassa @cabibbo78 @casadei_gardini @Gio_Marchegiani